New Therapies in Veterinary Oncology.

Mullin, Christine; Clifford, Craig A; Johannes, Chad M

Mullin, Christine; Clifford, Craig A; Johannes, Chad M.

Affiliation

Mullin C; BluePearl Pet Hospital - Malvern, 40 Three Tun Road, Malvern, PA 19355, USA.
Clifford CA; BluePearl Pet Hospital - Malvern, 40 Three Tun Road, Malvern, PA 19355, USA. Electronic address: Craig.clifford@bluepearlvet.com.
Johannes CM; Colorado State University, 300 West Drake Road, Fort Collins, CO 80526, USA.

Vet Clin North Am Small Anim Pract ; 54(3): 469-476, 2024 May.

Article in En | MEDLINE | ID: mdl-38184436

ABSTRACT

ABSTRACT

The expanding number of specialized oncology therapeutics available in veterinary oncology can make staying updated on the most recent advances challenging. This article summarizes the mechanism of action, available supporting data, and clinical use of three key veterinary cancer/supportive care therapeutics Laverdia-CA1, Canalevia-CA1, and Stelfonta. This information will help guide clinical use within your practice and can be incorporated into discussions with clients regarding the newest available options for their dogs with cancer.

Subject(s)

Dog Diseases; Neoplasms; Humans; Animals; Dogs; Neoplasms/therapy; Neoplasms/veterinary; Medical Oncology; Dog Diseases/therapy

Key words

Canalevia; Laverdia; Novel therapy; Stelfonta

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Dog Diseases / Neoplasms Type of study: Qualitative_research Limits: Animals / Humans Language: En Year: 2024 Type: Article

Fulltext

XML

PubMed Links

Search on Google